论文部分内容阅读
随机收集2013年6月~2014年6月长期在我院门诊治疗的2型糖尿病患者360例,通过问卷调查,调查患者的降糖方案,并比较不同降糖方案糖化血红蛋白(Hb A1c)的达标情况。结果以Hb A1c<7%作为血糖达标的标准,360例调查的2型糖尿病患者中,Hb A1c达标的有125例,占34.72%,其中应用单一口服降糖药的42例,占11.67%,Hb A1c达标的有14例,占33.33%;两种口服药的有75例,占20.83%,Hb A1c达标的有28例,占37.33%;应用三种口服药以上(含三种)的有128例,占35.56%,Hb A1c达标的有26例,占21.86%;单纯胰岛素治疗的有25例,占6.94%,Hb A1c达标的有9例,占36.00%;胰岛素联合口服降糖药的有90例,占25%,Hb A1c达标的有48例,占53.33%。结论门诊治疗的2型糖尿病患者,总体血糖达标率偏低,在上述的降糖治疗方案中,胰岛素联合口服降糖药的达标率最高,三种口服药以上(含三种)的患者达标率最低,总体的胰岛素使用率偏低,是影响血糖控制不达标的因素之一,建议尽早启动胰岛素治疗,有望改善门诊2型糖尿病患者的血糖达标状况。
A total of 360 patients with type 2 diabetes mellitus were selected randomly from June 2013 to June 2014 for outpatient treatment in our hospital. The patients’ hypoglycemic regimen was investigated through questionnaire survey and compared with the standard of Hb A1c Happening. Results HbA1c <7% was used as the standard of glycemic control. Of the 360 patients with type 2 diabetes, Hb A1c reached the standard of 125 (34.72%), of which 42 cases were single oral hypoglycemic agents (11.67%), Hb A1c reached the standard of 14 cases, accounting for 33.33%; two kinds of oral medication in 75 cases, accounting for 20.83%, Hb A1c standard compliance in 28 cases, accounting for 37.33%; the application of three oral drugs (including three) 128 cases, accounting for 35.56%, Hb A1c compliance of 26 cases, accounting for 21.86%; simple insulin treatment in 25 cases, accounting for 6.94%, Hb A1c compliance in 9 cases, accounting for 36.00%; insulin combination oral hypoglycemic agents There are 90 cases, accounting for 25%, 48 cases of Hb A1c compliance, accounting for 53.33%. Conclusion Outpatient treatment of patients with type 2 diabetes, the overall low blood sugar compliance rate, in the above hypoglycemic regimen, insulin and oral hypoglycemic agents to achieve the highest rate of three oral medication (including three) of the patients compliance rate The lowest overall insulin utilization rate is one of the factors that affect the non-compliance of glycemic control. It is recommended to start insulin therapy as soon as possible, which is expected to improve the glycemic compliance in outpatients with type 2 diabetes.